The Stago group, Asnières, France, recently completed the acquisition of HemoSonics LLC, Charlottesvilla, Va, a company specialized in the development of point-of-care testing systems.
With the acquisition of Hemosonics’ patented sonic estimation of elasticity via resonance (SEER) technology and its associated Quantra hemostasis analyzer, Stago seeks to expand opportunities for future growth. The acquisition is part of the company’s ongoing efforts to diversify its portfolio of medical devices.
“This significant step makes us very proud to contribute to the management of healthcare costs and to the improvement of patient outcomes worldwide,” says Lionel Viret, chairman of the board at Diagnostica Stago.
“Stago brings exceptional expertise in the field of thrombosis and hemostasis that will greatly advance our efforts to rapidly and effectively deliver a new standard of care for the management of bleeding in the critical care setting,” says Timothy Fischer, president and CEO of HemoSonics.
Ferghana Partners acted as exclusive financial advisor to HemoSonics for this transaction. For more information, visit Diagnostica Stago and HemoSonics.
